Crossmark

Dexamethasone for 12 weeks for reducing fatigue in patients receiving palliative chemotherapy: A Phase 3, Placebo-Controlled, Randomized Controlled Trial

Crossref DOI link: https://doi.org/10.1007/s00520-025-09807-w

Published Online: 2025-07-31

Published Print: 2025-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Radhakrishnan, Venkatraman

Gopalakrishnan, Vidhya

Vihari, Gundrathi Vamsi

Dasapathi, Venkata Siva Kiran Kumar

Perumal Kalaiyarasi, Jayachandran

Veeraiah, Surendran

Rajaraman, Swaminathan
License Information

Text and Data Mining valid from 2025-07-31

Version of Record valid from 2025-07-31
More Information

Article History

Received: 12 April 2025

Accepted: 24 July 2025

First Online: 31 July 2025

Declarations

:

: ASCO 2023 annual meeting.

: The Cancer Institute (W.I.A) Ethics Committee reviewed and approved the study protocol on 25 July 2018 (Reference number: IEC/2018/08). The study procedures adhered to the ethical standards of conduct outlined in the 2013 Declaration of Helsinki.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below